MarketCap
Facebook
X
Telegram
Akebia Therapeutics Long-Term Debt | AKBA
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.2 M | 38.7 M | 17.2 M | 34.1 M | 33.7 M | 96.4 M | 75.8 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 96.4 M | 17.2 M | 49.2 M |
Quarterly Long-Term Debt Akebia Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.8 M | 36.4 M | 47.6 M | 47.1 M | 46.5 M | 38.7 M | 38.4 M | 38 M | - | 17.2 M | 34.6 M | 18.5 M | 26.3 M | 34.1 M | 65.9 M | - | 32.6 M | 33.7 M | 97.2 M | 96.9 M | 96.6 M | 96.4 M | 96.4 M | 96.4 M | 96.4 M | 75.8 M | 75.8 M | 75.8 M | 75.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 97.2 M | 17.2 M | 57.8 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BeyondSpring
BYSI
|
307 K | $ 0.79 | 2.12 % | $ 32.5 M |  USA |
 |
Cabaletta Bio
CABA
|
2.88 M | $ 2.08 | 4.0 % | $ 209 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
15 K | $ 2.14 | 0.45 % | $ 3.52 M |  Israel |
 |
Capricor Therapeutics
CAPR
|
14.3 M | $ 7.78 | 0.11 % | $ 362 M | USA |
 |
Catalyst Biosciences
CBIO
|
303 K | $ 13.94 | 0.42 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
53.6 M | $ 2.99 | 1.36 % | $ 248 M | USA |
 |
Codexis
CDXS
|
40.1 M | $ 1.39 | 2.21 % | $ 121 M | USA |
 |
Cerus Corporation
CERS
|
10.2 M | $ 2.34 | 2.63 % | $ 446 M | USA |
 |
Certara
CERT
|
290 M | $ 10.07 | 7.59 % | $ 1.62 B | USA |
 |
Cullinan Management
CGEM
|
1.9 M | $ 16.04 | 3.42 % | $ 966 M | USA |
 |
Compugen Ltd.
CGEN
|
2.44 M | $ 2.31 | 0.43 % | $ 216 M | Israel |
 |
Coherus BioSciences
CHRS
|
1.46 M | $ 1.12 | 0.86 % | $ 131 M | USA |
 |
Celldex Therapeutics
CLDX
|
784 K | $ 32.59 | 2.97 % | $ 2.16 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.03 M | $ 3.41 | 1.46 % | $ 41.6 M | Israel |
 |
Cellectis S.A.
CLLS
|
27.7 M | $ 1.41 | 0.48 % | $ 141 M |  France |
 |
Cellectar Biosciences
CLRB
|
309 K | $ 1.67 | 0.56 % | $ 4.36 M | USA |
 |
Cocrystal Pharma
COCP
|
1.17 M | $ 1.11 | 1.72 % | $ 12.5 M | USA |
 |
Collegium Pharmaceutical
COLL
|
4.13 M | $ 21.87 | 0.05 % | $ 692 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
5.02 M | $ 122.03 | 4.99 % | $ 12.7 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
1.63 M | $ 5.85 | 0.16 % | $ 77.9 M | USA |
 |
Cardiff Oncology
CRDF
|
102 K | $ 1.14 | 1.79 % | $ 76.2 M | USA |
 |
Curis
CRIS
|
428 K | $ 0.79 | 0.1 % | $ 10.4 M | USA |
 |
CorMedix
CRMD
|
586 K | $ 7.26 | 0.97 % | $ 523 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
188 M | $ 57.34 | 3.45 % | $ 5.16 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
534 K | $ 10.74 | 0.09 % | $ 848 M | USA |
 |
Champions Oncology
CSBR
|
7 K | $ 4.97 | 0.61 % | $ 68.7 M | USA |
 |
CytomX Therapeutics
CTMX
|
4.24 M | $ 2.58 | 0.78 % | $ 356 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
725 K | $ 0.52 | 0.4 % | $ 5.75 M | USA |
 |
Cue Biopharma
CUE
|
2.29 M | $ 24.36 | 1.27 % | $ 2.31 B | USA |
 |
CEL-SCI Corporation
CVM
|
5.68 M | $ 2.42 | 4.76 % | $ 19.4 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
246 M | $ 62.7 | 0.2 % | $ 7.53 M | USA |
 |
Daré Bioscience
DARE
|
559 K | $ 0.84 | 0.04 % | $ 9.39 M | USA |
 |
DBV Technologies S.A.
DBVT
|
5.41 M | $ 10.44 | 0.47 % | $ 1.46 B | France |
 |
DiaMedica Therapeutics
DMAC
|
4 K | $ 8.42 | 2.31 % | $ 396 M | USA |
 |
Denali Therapeutics
DNLI
|
5.53 M | $ 19.91 | 0.41 % | $ 3.44 B | USA |
 |
Precision BioSciences
DTIL
|
4.9 M | $ 6.31 | 0.16 % | $ 80.9 M | USA |
 |
Dyadic International
DYAI
|
34.6 K | $ 0.45 | 0.31 % | $ 16.3 M | USA |
 |
Editas Medicine
EDIT
|
53.6 M | $ 2.79 | 6.49 % | $ 248 M | USA |
 |
Edesa Biotech
EDSA
|
19.8 K | $ 3.91 | 1.3 % | $ 22.2 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
383 K | $ 0.36 | 0.36 % | $ 16.5 M | Israel |
 |
Enanta Pharmaceuticals
ENTA
|
54.8 M | $ 12.6 | 0.93 % | $ 269 K | USA |
 |
Entera Bio Ltd.
ENTX
|
260 K | $ 2.62 | 0.69 % | $ 121 M | Israel |
 |
Equillium
EQ
|
356 K | $ 1.45 | 2.84 % | $ 83.1 M | USA |
 |
Eton Pharmaceuticals
ETON
|
21.8 M | $ 55.62 | 0.47 % | $ 1.5 B | USA |
 |
Evogene Ltd.
EVGN
|
1.48 M | $ 0.4 | 3.54 % | $ 3.15 M | Israel |
 |
Exelixis
EXEL
|
173 M | $ 58.85 | 0.79 % | $ 16 B | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
20.8 M | $ 3.15 | 0.62 % | $ 231 K | USA |
 |
Fate Therapeutics
FATE
|
73.3 M | $ 2.43 | 4.74 % | $ 289 M | USA |
 |
Fortress Biotech
FBIO
|
52.4 M | $ 2.09 | 2.96 % | $ 58.3 M | USA |